X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The net proceeds will used in the development of Multikine (leukocyte interleukin), which is designed to help the immune system target the tumor for the treatment of squamous cell carcinoma of the head and neck.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $7.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
The net proceeds will used in the development of Multikine (leukocyte interleukin), which is designed to help the immune system target the tumor for the treatment of squamous cell carcinoma of the head and neck.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $7.75 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2024
Details:
Indocin-Generic (indomethacin) oral suspension is a COX inhibitor which is now approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis & acute gouty arthritis.
Lead Product(s): Indomethacin
Therapeutic Area: Immunology Product Name: Indocin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The Company intends to use the net proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasia.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 20, 2023
Details:
Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Indocin (indomethacin) suppositories is a nonsteroidal anti-inflammatory drug that is indicated for the treatment of moderate to severe rheumatoid arthritis.
Lead Product(s): Indomethacin
Therapeutic Area: Immunology Product Name: Indocin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The Company intends to use the proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasia.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 17, 2023
Details:
Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2023
Details:
The net proceeds will fund the continued development of Multikine (leukocyte interleukin), an immunotherapeutic agent that is being developed as a potential first-line neoadjuvant therapy in patients with advanced primary squamous cell carcinoma of the head and neck.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 27, 2023
Details:
Multikine (leukocyte interleukin) is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
IRX-2 is a primary cell-derived multi-cytokine biologic immunotherapy in development for multiple solid tumor indications. IRX-2 is administered locally by subcutaneous injection and is designed to activate T cells to generate an anti-tumor response.
Lead Product(s): IRX-2,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: IRX-2
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
Multikine (Leukocyte Interleukin) is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients for their clinical trial.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 22, 2022
Details:
The collaboration received official approval this past Friday from the Nepal Health Research Council and is now commencing Phase II Clinical Trials of SJP-002C, for a novel oral therapy to mitigate the symptoms and hospitalizations associated with COVID-19.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Duke University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2022
Details:
Multikine (Leukocyte Interleukin, Injection) is an investigational cancer immunotherapy that is known to contain 14 natural human cytokines, the body’s immune system regulators and colony stimulating factors.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2021
Details:
Data indicate significant overall survival (OS) benefit for patients who received the Multikine® treatment regimen followed by surgery and radiotherapy, but not for patients who had chemotherapy added to the same treatment.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
The Company’s lead investigational therapy Multikine is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kingswood Capital Markets
Deal Size: $31.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2021
Details:
Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the treatment of cancer.
Lead Product(s): IRX-2,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: IRX-2
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NTN Buzztime
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Merger August 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
